Iradimed Co Net Income
| IRMD Stock | USD 103.08 2.07 1.97% |
As of the 11th of February 2026, Iradimed retains the Risk Adjusted Performance of 0.1635, market risk adjusted performance of 0.8707, and Downside Deviation of 1.57. Iradimed technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Iradimed jensen alpha, and the relationship between the coefficient of variation and potential upside to decide if Iradimed is priced fairly, providing market reflects its last-minute price of 103.08 per share. Given that Iradimed Co has jensen alpha of 0.307, we strongly advise you to confirm Iradimed's regular market performance to make sure the company can sustain itself at a future point.
Iradimed Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 14.4616 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income Applicable To Common Shares | 14.8 M | 15.5 M | |
| Net Income | 22.1 M | 23.2 M | |
| Net Income From Continuing Ops | 22.1 M | 23.2 M | |
| Net Income Per Share | 1.37 | 1.43 | |
| Net Income Per E B T | 0.91 | 0.58 |
Iradimed | Net Income | Build AI portfolio with Iradimed Stock |
Analyzing Iradimed's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Iradimed's current valuation and future prospects.
Latest Iradimed's Net Income Growth Pattern
Below is the plot of the Net Income of Iradimed Co over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Iradimed financial statement analysis. It represents the amount of money remaining after all of Iradimed Co operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Iradimed's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Iradimed's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 19.23 M | 10 Years Trend |
|
Net Income |
| Timeline |
Iradimed Net Income Regression Statistics
| Arithmetic Mean | 8,432,767 | |
| Geometric Mean | 4,568,004 | |
| Coefficient Of Variation | 93.32 | |
| Mean Deviation | 6,414,762 | |
| Median | 7,214,545 | |
| Standard Deviation | 7,869,751 | |
| Sample Variance | 61.9T | |
| Range | 22.7M | |
| R-Value | 0.88 | |
| Mean Square Error | 15.2T | |
| R-Squared | 0.77 | |
| Slope | 1,367,562 | |
| Total Sum of Squares | 990.9T |
Iradimed Net Income History
Other Fundumenentals of Iradimed
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Iradimed Net Income component correlations
Iradimed Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Iradimed is extremely important. It helps to project a fair market value of Iradimed Stock properly, considering its historical fundamentals such as Net Income. Since Iradimed's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Iradimed's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Iradimed's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Health Care Equipment & Supplies sector continue expanding? Could Iradimed diversify its offerings? Factors like these will boost the valuation of Iradimed. Market participants price Iradimed higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Iradimed data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.079 | Dividend Share 0.68 | Earnings Share 1.65 | Revenue Per Share | Quarterly Revenue Growth 0.157 |
Iradimed's market price often diverges from its book value, the accounting figure shown on Iradimed's balance sheet. Smart investors calculate Iradimed's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Iradimed's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Iradimed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Iradimed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iradimed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Iradimed 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Iradimed's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Iradimed.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in Iradimed on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Iradimed Co or generate 0.0% return on investment in Iradimed over 90 days. Iradimed is related to or competes with InMode, Axogen, Tandem Diabetes, Adapthealth Corp, Integra LifeSciences, Claritev, and Opko Health. IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging compatible medical devi... More
Iradimed Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Iradimed's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Iradimed Co upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.57 | |||
| Information Ratio | 0.1451 | |||
| Maximum Drawdown | 7.15 | |||
| Value At Risk | (2.24) | |||
| Potential Upside | 2.3 |
Iradimed Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Iradimed's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Iradimed's standard deviation. In reality, there are many statistical measures that can use Iradimed historical prices to predict the future Iradimed's volatility.| Risk Adjusted Performance | 0.1635 | |||
| Jensen Alpha | 0.307 | |||
| Total Risk Alpha | 0.1568 | |||
| Sortino Ratio | 0.1642 | |||
| Treynor Ratio | 0.8607 |
Iradimed February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1635 | |||
| Market Risk Adjusted Performance | 0.8707 | |||
| Mean Deviation | 1.15 | |||
| Semi Deviation | 1.21 | |||
| Downside Deviation | 1.57 | |||
| Coefficient Of Variation | 506.66 | |||
| Standard Deviation | 1.77 | |||
| Variance | 3.14 | |||
| Information Ratio | 0.1451 | |||
| Jensen Alpha | 0.307 | |||
| Total Risk Alpha | 0.1568 | |||
| Sortino Ratio | 0.1642 | |||
| Treynor Ratio | 0.8607 | |||
| Maximum Drawdown | 7.15 | |||
| Value At Risk | (2.24) | |||
| Potential Upside | 2.3 | |||
| Downside Variance | 2.45 | |||
| Semi Variance | 1.46 | |||
| Expected Short fall | (1.27) | |||
| Skewness | 1.79 | |||
| Kurtosis | 10.73 |
Iradimed Backtested Returns
Iradimed appears to be very steady, given 3 months investment horizon. Iradimed holds Efficiency (Sharpe) Ratio of 0.22, which attests that the entity had a 0.22 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Iradimed, which you can use to evaluate the volatility of the firm. Please utilize Iradimed's Market Risk Adjusted Performance of 0.8707, risk adjusted performance of 0.1635, and Downside Deviation of 1.57 to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Iradimed holds a performance score of 17. The company retains a Market Volatility (i.e., Beta) of 0.39, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Iradimed's returns are expected to increase less than the market. However, during the bear market, the loss of holding Iradimed is expected to be smaller as well. Please check Iradimed's potential upside, rate of daily change, and the relationship between the sortino ratio and skewness , to make a quick decision on whether Iradimed's current trending patterns will revert.
Auto-correlation | 0.18 |
Very weak predictability
Iradimed Co has very weak predictability. Overlapping area represents the amount of predictability between Iradimed time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Iradimed price movement. The serial correlation of 0.18 indicates that over 18.0% of current Iradimed price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.18 | |
| Spearman Rank Test | 0.07 | |
| Residual Average | 0.0 | |
| Price Variance | 7.56 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Iradimed Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Iradimed Co reported net income of 19.23 M. This is 94.36% lower than that of the Health Care Equipment & Supplies sector and 91.92% lower than that of the Health Care industry. The net income for all United States stocks is 96.63% higher than that of the company.
Iradimed Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Iradimed's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Iradimed could also be used in its relative valuation, which is a method of valuing Iradimed by comparing valuation metrics of similar companies.Iradimed is currently under evaluation in net income category among its peers.
Iradimed Current Valuation Drivers
We derive many important indicators used in calculating different scores of Iradimed from analyzing Iradimed's financial statements. These drivers represent accounts that assess Iradimed's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Iradimed's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 276.4M | 570.5M | 355.4M | 598.3M | 538.4M | 565.4M | |
| Enterprise Value | 229.1M | 511.0M | 299.6M | 550.5M | 495.5M | 520.3M |
Iradimed ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Iradimed's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Iradimed's managers, analysts, and investors.Environmental | Governance | Social |
Iradimed Institutional Holders
Institutional Holdings refers to the ownership stake in Iradimed that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Iradimed's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Iradimed's value.| Shares | Northern Trust Corp | 2025-06-30 | 143.2 K | Millennium Management Llc | 2025-06-30 | 111.6 K | Bank Of New York Mellon Corp | 2025-06-30 | 103.8 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 91.5 K | Uniplan Investment Counsel, Inc. | 2025-06-30 | 80.3 K | Roubaix Capital, Llc | 2025-06-30 | 71.5 K | Charles Schwab Investment Management Inc | 2025-06-30 | 67.3 K | Envestnet Asset Management Inc | 2025-06-30 | 67.1 K | Rice Hall James & Associates, Llc | 2025-06-30 | 64 K | Blackrock Inc | 2025-06-30 | 962.3 K | Nine Ten Capital Management Llc | 2025-06-30 | 872 K |
Iradimed Fundamentals
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.15 | ||||
| Profit Margin | 0.26 % | ||||
| Operating Margin | 0.32 % | ||||
| Current Valuation | 1.16 B | ||||
| Shares Outstanding | 12.72 M | ||||
| Shares Owned By Insiders | 36.79 % | ||||
| Shares Owned By Institutions | 57.50 % | ||||
| Number Of Shares Shorted | 453.88 K | ||||
| Price To Earning | 28.70 X | ||||
| Price To Book | 12.41 X | ||||
| Price To Sales | 15.16 X | ||||
| Revenue | 73.24 M | ||||
| Gross Profit | 62.05 M | ||||
| EBITDA | 22.78 M | ||||
| Net Income | 19.23 M | ||||
| Cash And Equivalents | 55.59 M | ||||
| Cash Per Share | 4.42 X | ||||
| Total Debt | 154.69 K | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 12.83 X | ||||
| Book Value Per Share | 7.73 X | ||||
| Cash Flow From Operations | 25.62 M | ||||
| Short Ratio | 5.21 X | ||||
| Earnings Per Share | 1.65 X | ||||
| Price To Earnings To Growth | 4.46 X | ||||
| Target Price | 99.0 | ||||
| Number Of Employees | 160 | ||||
| Beta | 1.14 | ||||
| Market Capitalization | 1.22 B | ||||
| Total Asset | 98.33 M | ||||
| Retained Earnings | 56.79 M | ||||
| Working Capital | 66.73 M | ||||
| Current Asset | 33.95 M | ||||
| Current Liabilities | 2.89 M | ||||
| Annual Yield | 0.01 % | ||||
| Net Asset | 98.33 M | ||||
| Last Dividend Paid | 0.68 |
About Iradimed Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Iradimed Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Iradimed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Iradimed Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Iradimed is a strong investment it is important to analyze Iradimed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Iradimed's future performance. For an informed investment choice regarding Iradimed Stock, refer to the following important reports:Check out You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Will Health Care Equipment & Supplies sector continue expanding? Could Iradimed diversify its offerings? Factors like these will boost the valuation of Iradimed. Market participants price Iradimed higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Iradimed data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.079 | Dividend Share 0.68 | Earnings Share 1.65 | Revenue Per Share | Quarterly Revenue Growth 0.157 |
Iradimed's market price often diverges from its book value, the accounting figure shown on Iradimed's balance sheet. Smart investors calculate Iradimed's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Iradimed's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Iradimed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Iradimed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iradimed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.